SCHEMBL2471028

SCHEMBL2471028

COc1ccccc1C(=O)NC(C1(c2ccccc2)CCNCC1)S(=O)(=O)n1ccnc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 2/20 0.39
SLC6A9 P48067 1/20 0.38
ITGA4 P13612 1/20 0.37
ITGB7 P26010 1/20 0.37
KCNA3 P22001 6/20 0.37
CASP3 P42574 1/20 0.36
POLB P06746 2/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2467171 0.85 SLC6A9 (0.40) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2470694 0.81 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2468926 0.81 KCNA3 (0.39) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2471969 0.81 POLB (0.40) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2467857 0.81 ALDH1A1 (0.45) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2469730 0.81 ALDH1A1 (0.45) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2470190 0.80 SLC6A9 (0.42) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2468331 0.80 ALDH1A1 (0.44) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2469428 0.80 ALDH1A1 (0.44) ALDH1A1MEN1KMT2AHPGDSLC6A9
SCHEMBL2468258 0.79 SLC6A9 (0.40) ALDH1A1MEN1KMT2AHPGDSLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 ALDH1A1 3941/4885MEN1 3501/4885KMT2A 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.